Patents by Inventor Henry R. Maun

Henry R. Maun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-tryptase antibodies, compositions thereof, and uses thereof
    Patent number: 11939396
    Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: March 26, 2024
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Janet Jackman, James T. Koerber, Mason Lu, Henry R. Maun, Kathila Rajapaksa, Saroja Ramanujan, Tracy Staton, Lawren Wu, Tangsheng Yi
  • USE OF KLK5 ANTAGONISTS FOR THE TREATMENT OF A DISEASE
    Publication number: 20230416825
    Abstract: Provided herein are methods of treating a subject, methods of predicting the response of a subject and selecting a subject suffering from a disease associated with KLK5, such as asthma or Netherton Syndrome. In particular, provided herein are uses of KLK5 antagonists for the treatment or diagnosis of asthma or Netherton Sydrome, such as an antibody or an Fc fusion polypeptide as well as pharmaceutical formulations comprising the same.
    Type: Application
    Filed: March 29, 2023
    Publication date: December 28, 2023
    Applicant: Genentech, Inc.
    Inventors: Amy Dressen, David B. Iaea, Moulay Hicham Alaoui Ismaili, Janet K. Jackman, Robert A. Lazarus, Kelly Michele Loyet, Henry R. Maun, Brian Louis Yaspan, Tangsheng Yi, Joseph R. Arron, Hilda Y Hernandez-Barry
  • ANTI-TRYPTASE ANTIBODIES, COMPOSITIONS THEREOF, AND USES THEREOF
    Publication number: 20200325248
    Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.
    Type: Application
    Filed: June 30, 2020
    Publication date: October 15, 2020
    Inventors: Xiaocheng CHEN, Mark DENNIS, Janet JACKMAN, James T. KOERBER, Mason LU, Henry R. MAUN, Kathila RAJAPAKSA, Saroja RAMANUJAN, Tracy STATON, Lawren WU, Tangsheng YI
  • Anti-tryptase antibodies, compositions thereof, and uses thereof
    Patent number: 10752703
    Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: August 25, 2020
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Janet Jackman, James T. Koerber, Mason Lu, Henry R. Maun, Kathila Rajapaksa, Saroja Ramanujan, Tracy Staton, Lawren Wu, Tangsheng Yi
  • Anti-tryptase antibodies, compositions thereof, and uses thereof
    Patent number: 10738131
    Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: August 11, 2020
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Janet Jackman, James T. Koerber, Mason Lu, Henry R. Maun, Kathila Rajapaksa, Saroja Ramanujan, Tracy Staton, Lawren Wu, Tangsheng Yi
  • Chagasin-based scaffold compositions, methods, and uses
    Patent number: 10562946
    Abstract: Provided are novel, non-naturally occurring chagasin scaffold proteins derived from chagasin or chagasin-like protease inhibitor proteins. Also provided are libraries of non-naturally occurring chagasin scaffold proteins and methods of using such libraries to generate non-naturally occurring chagasin scaffold proteins that specifically bind to a target ligand. The present invention further provides methods of using non-naturally occurring chagasin protein scaffold that bind to a target ligand, including diagnostic and therapeutic compositions and methods. The invention also provides novel non-naturally occurring chagasin scaffold proteins that specifically bind low density lipoprotein receptor-related protein 6 (LRP6) and novel non-naturally occurring chagasin scaffold proteins that specifically bind vascular endothelial growth factor (VEGF).
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: February 18, 2020
    Assignee: Genentech, Inc.
    Inventors: Robert A. Lazarus, Henry R. Maun
  • ANTI-TRYPTASE ANTIBODIES, COMPOSITIONS THEREOF, AND USES THEREOF
    Publication number: 20190367637
    Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.
    Type: Application
    Filed: August 19, 2019
    Publication date: December 5, 2019
    Inventors: Xiaocheng CHEN, Mark DENNIS, Janet JACKMAN, James T. KOERBER, Mason LU, Henry R. MAUN, Kathila RAJAPAKSA, Saroja RAMANUJAN, Tracy STATON, Lawren WU, Tangsheng YI
  • USE OF KLK5 ANTAGONISTS FOR TREATMENT OF A DISEASE
    Publication number: 20190078160
    Abstract: Provided herein are methods of treating a subject, methods of predicting the response of a subject and selecting a subject suffering from a disease associated with KLK5, such as asthma or Netherton Syndrome. In particular, provided herein are uses of KLK5 antagonists for the treatment or diagnosis of asthma or Netherton Syndrome, such as an antibody or an Fc fusion polypeptide as well as pharmaceutical formulations comprising the same.
    Type: Application
    Filed: April 20, 2018
    Publication date: March 14, 2019
    Applicant: Genentech, Inc.
    Inventors: Amy Dressen, David B. Iaea, Moulay Hicham Alaoui Ismaili, Janet K. Jackman, Robert A. Lazarus, Kelly Loyet, Henry R. Maun, Brian L. Yaspan, Tangsheng Yi, Joseph R. Arron, Hilda Y. Hernandez-Barry
  • ANTI-TRYPTASE ANTIBODIES, COMPOSITIONS THEREOF, AND USES THEREOF
    Publication number: 20180230233
    Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.
    Type: Application
    Filed: February 9, 2018
    Publication date: August 16, 2018
    Inventors: Xiaocheng CHEN, Mark DENNIS, Janet JACKMAN, James T. KOERBER, Mason LU, Henry R. MAUN, Kathila RAJAPAKSA, Saroja RAMANUJAN, Tracy STATON, Lawren WU, Tangsheng YI
  • CHAGASIN-BASED SCAFFOLD COMPOSITIONS, METHODS, AND USES
    Publication number: 20170174733
    Abstract: Provided are novel, non-naturally occurring chagasin scaffold proteins derived from chagasin or chagasin-like protease inhibitor proteins. Also provided are libraries of non-naturally occurring chagasin scaffold proteins and methods of using such libraries to generate non-naturally occurring chagasin scaffold proteins that specifically bind to a target ligand. The present invention further provides methods of using non-naturally occurring chagasin protein scaffold that bind to a target ligand, including diagnostic and therapeutic compositions and methods. The invention also provides novel non-naturally occurring chagasin scaffold proteins that specifically bind low density lipoprotein receptor-related protein 6 (LRP6) and novel non-naturally occurring chagasin scaffold proteins that specifically bind vascular endothelial growth factor (VEGF).
    Type: Application
    Filed: June 19, 2015
    Publication date: June 22, 2017
    Applicant: Genentech, Inc.
    Inventors: Robert A. LAZARUS, Henry R. MAUN
  • Variant Hhip1 protein and methods and uses thereof
    Patent number: 8623997
    Abstract: The present invention is directed to derivatives of Hhip1 and methods of using the same for treatment and diagnosis of cancer in mammals.
    Type: Grant
    Filed: June 1, 2009
    Date of Patent: January 7, 2014
    Assignees: Curis, Inc., Genentech, Inc.
    Inventors: Ivan Bosanac, Sarah G. Hymowitz, Robert A. Lazarus, Henry R. Maun, Suzanna J. Scales, Xiaohui Wen
  • VARIANT HHIP1 PROTEIN AND METHODS AND USES THEREOF
    Publication number: 20110129457
    Abstract: The present invention is directed to derivatives of Hhip1 and methods of using the same for treatment and diagnosis of cancer in mammals.
    Type: Application
    Filed: June 1, 2009
    Publication date: June 2, 2011
    Inventors: Ivan Bosanac, Sarah G. Hymowitz, Robert A. Lazarus, Henry R. Maun, Suzanna J. Scales, Xiaohui Wen
  • FVIIa antagonists
    Patent number: 7164002
    Abstract: This invention provides novel compounds which prevent or block a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention bind Factor VIIa (FVIIa ), its zymogen Factor VII (FVII). The invention also provides pharmaceutical compositions comprising the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.
    Type: Grant
    Filed: January 30, 2003
    Date of Patent: January 16, 2007
    Assignee: Genentech, Inc.
    Inventors: Robert A. Lazarus, Henry R. Maun
  • FVIIa antagonists
    Publication number: 20040087767
    Abstract: This invention provides novel compounds which prevent or block a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa , FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention bind Factor VIIa (FVIIa ), its zymogen Factor VII (FVII). The invention also provides pharmaceutical compositions comprising the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.
    Type: Application
    Filed: January 30, 2003
    Publication date: May 6, 2004
    Applicant: GENENTECH, INC.
    Inventors: Robert A. Lazarus, Henry R. Maun